Pfizer (NYSE:PFE) Stock Price Expected to Rise, Guggenheim Analyst Says

Pfizer (NYSE:PFE) had its price target upped by Guggenheim from $35.00 to $36.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Guggenheim’s price objective would suggest a potential upside of 31.94% from the stock’s previous close.

PFE has been the topic of a number of other research reports. Zacks Research upgraded Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. HSBC lifted their target price on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, March 17th. UBS Group began coverage on shares of Pfizer in a research report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 target price on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research note on Thursday, January 22nd. Finally, Wolfe Research set a $24.00 price target on shares of Pfizer and gave the stock an “underperform” rating in a report on Wednesday, December 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $28.19.

Pfizer Stock Performance

Shares of PFE opened at $27.29 on Tuesday. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The firm has a market cap of $155.16 billion, a PE ratio of 20.06 and a beta of 0.47. Pfizer has a 12 month low of $20.92 and a 12 month high of $27.94. The stock has a fifty day moving average price of $26.78 and a 200-day moving average price of $25.65.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. During the same period in the previous year, the business earned $0.63 EPS. The firm’s revenue for the quarter was down 1.2% on a year-over-year basis. Equities research analysts predict that Pfizer will post 2.95 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pfizer

A number of large investors have recently bought and sold shares of the company. Norges Bank purchased a new stake in shares of Pfizer in the 2nd quarter valued at $2,270,157,000. Morgan Stanley raised its holdings in shares of Pfizer by 19.2% during the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after purchasing an additional 14,342,946 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Pfizer by 38.9% during the fourth quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company’s stock worth $1,208,023,000 after purchasing an additional 13,581,757 shares during the last quarter. Franklin Resources Inc. lifted its position in Pfizer by 47.8% during the third quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock valued at $638,787,000 after purchasing an additional 8,108,887 shares during the period. Finally, Janus Henderson Group PLC lifted its position in Pfizer by 577.5% during the fourth quarter. Janus Henderson Group PLC now owns 8,786,084 shares of the biopharmaceutical company’s stock valued at $218,817,000 after purchasing an additional 7,489,189 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive Phase 3 topline for TALAPRO-3 (TALZENNA + XTANDI) in homologous recombination repair prostate cancer — strengthens Pfizer’s oncology franchise and supports future revenue and labeling opportunities. Pfizer Announces Positive TALAPRO-3 Results
• Positive Sentiment: Guggenheim raised its price target to $36 and upgraded to a buy — a high-profile analyst lift that can drive demand and re-rate the stock if others follow. Benzinga: Guggenheim Raises Price Target
• Positive Sentiment: Analyst and media bullishness on upside from a key prostate‑cancer trial — several write-ups project significant appreciation (examples cite targets near $36) if oncology readouts continue to progress. 247WallSt: Pfizer Could Hit $36
• Positive Sentiment: Coverage highlighting Pfizer as a high‑yield, undervalued play with pipeline catalysts — these narratives attract income and value buyers while emphasizing long‑term upside from new assets. 24/7 Wall St: 6.5% Yielding Dividend Payer
• Positive Sentiment: Pfizer CFO discussed recent oncology milestones on NYSE Live — management visibility on progress helps reduce execution uncertainty and supports investor confidence. Yahoo Finance: CFO Highlights Oncology Milestones
• Neutral Sentiment: Company scheduled a public webcast and analyst call for May 5 to discuss Q1 results and the Q1 performance report — provides a near-term event for updated guidance and pipeline commentary. Yahoo Finance: May 5 Webcast
• Negative Sentiment: Lyme vaccine readout shows ~73% efficacy but missed the trial’s primary statistical target due to low case numbers — clinical/regulatory uncertainty remains and could delay approvals or reduce near-term impact. Yahoo Finance: Pfizer Lyme Vaccine Data
• Negative Sentiment: Competitor momentum: Bristol Myers’ Opdivo label expansions intensify IO competition — pricing and market-share pressure in oncology could constrain long‑term upside for some Pfizer programs. Yahoo Finance: BMY Opdivo Expansion
• Negative Sentiment: Valneva’s stock plunge after mixed Lyme results highlights partner/regulatory risk — market volatility in related vaccine news can spill over to Pfizer sentiment. Yahoo Finance: VALN Mixed Results

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.